• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Phase II Study Supports Potential for Genentech ’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

    Phase II Study Supports Potential for Genentech ’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

  2. PharmaPoint: $26.71 Billion Non-Small Cell Lung Cancer (NSCLC) Market - Global Drug Forecast and Analysis to 2025 - Research and Markets

    PharmaPoint: $26.71 Billion Non-Small Cell Lung Cancer (NSCLC) Market - Global Drug Forecast and Analysis to 2025 - Research and Markets

  3. Clovis Oncology Announces 2016 Operating Results

    Clovis Oncology Announces 2016 Operating Results

  4. U.S. Obtains Records in Lobbyist Probe -- WSJ

    U.S. Obtains Records in Lobbyist Probe -- WSJ

  5. FBI Searches for Possible Accomplices in Probe of Fallen K Street Lobbyist

    FBI Searches for Possible Accomplices in Probe of Fallen K Street Lobbyist

  6. Internationally Renowned City of Hope Scientist Arthur D. Riggs, Ph.D., Named Samuel Rahbar Chair in Diabetes & Drug Discovery

    Internationally Renowned City of Hope Scientist Arthur D. Riggs, Ph.D., Named Samuel Rahbar Chair in Diabetes & Drug Discovery

  7. ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences

    ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences

  8. Roche Unfazed by Trump's Drug-Price Comments as Profit Rises -- 2nd Update

    Roche Unfazed by Trump's Drug-Price Comments as Profit Rises -- 2nd Update

  9. Social Security Tips For Couples

    Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...

  10. Tuttle Tactical Management Weekly Market Commentary

    Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...

123

©2017 Morningstar Advisor. All right reserved.